ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h [i] j k l m n o p q r s t u v w x y z
  • Abstract Number: 0986
    Ianalumab (VAY736) Safety and Efficacy in Patients with Sjögren’s Syndrome: 52 Week Results from a Randomized, Placebo-controlled, Phase 2b Dose-ranging Trial
  • Abstract Number: 0037
    Identification and Validation of Four Circulating Autoantibodies Associated with the ACPA Status in Early Rheumatoid Arthritis
  • Abstract Number: 0533
    Identification of a Novel Susceptibility Locus for Small Vessel Vasculitis with Autoantibodies Against Myeloperoxidase
  • Abstract Number: 0051
    Identification of Biomarkers and Deregulated Pathways in Psoriatic Arthritis Through Proteomic Analysis of Synovial Fluid
  • Abstract Number: 0478
    Identification of Clinical Phenotypes of Hand Osteoarthritis Using Hierarchical Clustering Method
  • Abstract Number: 1435
    Identification of Distinct Fibroblast Populations in Systemic Sclerosis 3D Skin Tissues with Single Cell Omics
  • Abstract Number: 1489
    Identification of Mitochondrial Antigens Targeted by Autoantibodies in Systemic Lupus Erythematosus (SLE)
  • Abstract Number: 0442
    Identification of Plexin D1 on Circulating Extracellular Vesicles as a Potential Biomarker of Polymyositis and Dermatomyositis
  • Abstract Number: 1363
    Identification of PsA Phenotypes with Machine Learning Analytics Using Data from a Phase 3 Clinical Trial Program of Guselkumab in a Bio-naïve Population of Patients with PsA
  • Abstract Number: 0449
    Identification of Serum Protein Biomarkers at Baseline to Distinguish Radiographic Progressors from Non-Progressors in Patients with Active Psoriatic Arthritis
  • Abstract Number: 0255
    Identification of Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
  • Abstract Number: 1220
    Identification of Underlying Disease Domains by Longitudinal Latent Factor Analysis for Secukinumab Treated Patients in Psoriatic Arthritis and Rheumatoid Arthritis Trials
  • Abstract Number: 1932
    Identifying Clusters of Longitudinal Autoantibody Profiles Associated with Systemic Lupus Erythematosus Disease Outcomes
  • Abstract Number: 0856
    Identifying COVID-19 Infection Rates and Outcomes in Patients with Systemic Lupus Erythematosus
  • Abstract Number: 0160
    Identifying Erosive Disease from Radiology Reports of Veterans with Inflammatory Arthritis with Natural Language Processing
  • Abstract Number: 0357
    Identifying Predictors of Unemployment in Axial Spondyloarthropathy: Data from the Ankylosing Spondylitis Registry of Ireland
  • Abstract Number: 1650
    Identifying Trajectories and Endotypes in the Evolution of Pre-Rheumatoid Arthritis with Autoantibody Testing and Artificial Adaptive System Analysis
  • Abstract Number: 0450
    Identifying Trajectories of Radiographic Spinal Disease in Ankylosing Spondylitis
  • Abstract Number: 0291
    IgA Anti-Cyclic Citrullinated Peptide Antibodies in Bronchoalveolar Lavage Fluid from Patients with Idiopathic Pulmonary Fibrosis Are Associated with Reduced Mortality
  • Abstract Number: 0553
    IgG from Systemic Sclerosis Patients Induce a Profibrosing and Serotype-dependent Phenotype in Normal Dermal Fibroblast: A Multi-omics Study
  • Abstract Number: 0209
    IgG4 Related Disease: Response to Immunosuppressive Therapy – A Single Centre Retrospective Study in the United Kingdom
  • Abstract Number: 1906
    IL-13Ra1-Mediated Signaling Regulates Age-Associated/Autoimmune B-Cell Expansion and Lupus Pathogenesis
  • Abstract Number: 1937
    IL-16 Is Linked to Lupus Nephritis Activity
  • Abstract Number: 0032
    IL-40: A New B-cell Associated Cytokine Up-regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates with Disease Activity, Autoantibodies and NETosis
  • Abstract Number: 1455
    IL1β mRNA Expressions in Peripheral Blood Mononuclear Cells Increase and May Associate with Cartilage Damage of the Respiratory Tract Probably Through Matrix metalloproteinase-3 Production in Patients with Relapsing Polychondritis
  • Abstract Number: 0469
    Imaging Characteristics in Patients with Spondyloarthritis Using a Novel Heel Enthesitis Magnetic Resonance Imaging Scoring (HEMRIS) System: Post-hoc Analysis of a Phase 3 Secukinumab Trial
  • Abstract Number: 0174
    Imaging Neoangiogenesis in Rheumatoid Arthritis II (INIRA II): Whole-body Synovial Uptake of 99mTc-Maraciclatide Correlates with Power Doppler Ultrasound and Serum Neoangiogenic Biomarkers
  • Abstract Number: 1499
    Imbalance Between T Follicular Cells and T Regulatory Cells Involved in High Fat-Diet Associated Lupus Development in MRL/lpr Mice
  • Abstract Number: 0712
    Immune Checkpoint Inhibitor-related Myotoxicity : Musculoskeletal and/or Neuromuscular Junction Disorder ?
  • Abstract Number: 0034
    Immune Complexes Contain Novel Acetylated Antigens in the Synovial Fluid of RA Patients
  • Abstract Number: 1546
    Immune Responses to COVID-19 Vaccines in Patients Using Immunosuppressive Medication for Inflammatory Arthritis – An Observational Study of 1500 Patients
  • Abstract Number: 1557
    Immunogenicity and Safety of an Inactivated Virus Vaccine Against SARS-CoV-2 in Patients with Autoimmune Rheumatic Diseases
  • Abstract Number: 0501
    Immunogenicity of a Single Dose of Covid-19 Vaccination in Patients with Systemic Sclerosis with or Without Immunosupression
  • Abstract Number: 0963
    Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRDs)
  • Abstract Number: L01
    Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full Vaccination in Patients with Inflammatory Rheumatic Diseases
  • Abstract Number: 0835
    Immunogenicity of Rituximab Biosimilar GP2013 in Chronic Inflammatory Rheumatic Disorders in Daily Clinical Practice
  • Abstract Number: 0978
    Immunological and Clinical Features of Untreated Juvenile Dermatomyositis Patients with Elevated Neopterin
  • Abstract Number: 0948
    Immunometabolism of Neutrophils in Antiphospholipid Syndrome (APS)
  • Abstract Number: 1914
    Immunomodulatory and Immunosuppressive Medication Modification Among Rheumatology Patients at the Time of COVID-19 Vaccination
  • Abstract Number: 0692
    Immunophenotyping of Inclusion Body Myositis Blood T Cells: Pathogenic and Biomarker Implications
  • Abstract Number: 0457
    Immunosuppression Attenuates Antibody and Neutralization Titers in Patients with Chronic Inflammatory Disease Following SARS-CoV-2 Vaccination
  • Abstract Number: 0072
    Immunosuppression Use in Primary Antiphospholipid Antibody Positive Patients: Descriptive Analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
  • Abstract Number: 0690
    Impact of Achieving 2016 ACR/EULAR Response Criteria on Patient Centered Outcome Measures in Myositis
  • Abstract Number: 0925
    Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs
  • Abstract Number: 1344
    Impact of Achieving Minimal Disease Activity on Patient-Reported Outcome Measures and Disease Activity Among Patients with Psoriatic Arthritis Treated with Biologic and Targeted Synthetic DMARDs
  • Abstract Number: 1279
    Impact of Active Lupus Nephritis in Patient-Reported Outcomes from a Latin American, Multicenter Lupus Cohort
  • Abstract Number: 1909
    Impact of Antimalarial Adherence on Cardiovascular Mortality Among Patients with Newly Diagnosed Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-based Study
  • Abstract Number: 0605
    Impact of Area of Residence on Perceptions of Health and Disease Activity in Ethnic Minorities with Rheumatoid Arthritis in an Urban Setting
  • Abstract Number: 1327
    Impact of BMI on Treatment Response Among PsA Patients Initiating TNF Inhibitors, IL17 Inhibitors and Oral Small Molecules
  • Abstract Number: 0632
    Impact of COVID-19 and Telehealth on RAPID3 Screening in an Academic Rheumatology Practice: Identifying Disparities in Care
  • Abstract Number: 1537
    Impact of COVID-19 Infection on Patient-Reported Outcomes in Rheumatic Disease Patients: A Cross Sectional Study
  • Abstract Number: 0275
    Impact of Disease Activity on Left Ventricular Diastolic Dysfunction in Rheumatoid Arthritis Patients
  • Abstract Number: 0234
    Impact of Early Pain Improvement on Patient-reported Outcomes in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial
  • Abstract Number: 0372
    Impact of Gender and Age on Ankylosing Spondylitis Patient Profiles at Golimumab Initiation and 12-Month Outcomes
  • Abstract Number: 1793
    Impact of Gender and Age on Psoriatic Arthritis Patient Profiles at Golimumab Initiation and 12-Month Outcomes
  • Abstract Number: 1361
    Impact of Intermediate Treatment Interruption on Secukinumab Efficacy in Patients with Active Psoriatic Arthritis and Ankylosing Spondylitis: Interim Analysis Results from the SERENA Study
  • Abstract Number: 0270
    Impact of Macrophage Cholesterol Loading Capacity and Interactions with Treatments on Cardiovascular Risk and Coronary Atherosclerosis Burden in Rheumatoid Arthritis
  • Abstract Number: 1057
    Impact of Osteoarthritis in Younger Adults
  • Abstract Number: 0376
    Impact of Patient and Disease Characteristics on Global Functioning and Health in Patients with Axial Spondyloarthritis: A Bayesian Network Analysis of Data from an Early axSpA Cohort
  • Abstract Number: 1680
    Impact of Race on the Efficacy and Safety of Tofacitinib in Patients with RA: A Post Hoc Analysis of Phase 2, 3, and 3b/4 Clinical Trials
  • Abstract Number: 1230
    Impact of Serologic Status on Clinical Responses to Upadacitinib or Abatacept in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Biologic DMARDs: Sub-Group Analysis from the Phase 3 SELECT-CHOICE Study
  • Abstract Number: 0959
    Impact of Systemic Lupus Disease Activity State on Flare Risk After Hydroxychloroquine Maintenance, Reduction or Discontinuation in a Multinational Inception Cohort
  • Abstract Number: 1591
    Impact of the COVID-19 Pandemic and Lockdown on Wellbeing on Patients with Rheumatic Diseases. Results from the REUMAVID Study (Phase 1)
  • Abstract Number: 1623
    Impact of the COVID-19 Pandemic on Presentation of JIA to Pediatric Rheumatology Care in Canada
  • Abstract Number: 1599
    Impact of the COVID-19 Pandemic on the Quality of Life of Patients with Rheumatic Conditions: A Qualitative Analysis of Perceived Risk and Decision Making
  • Abstract Number: 1309
    Impact of the Number of Comorbidities on the Outcome Measures and on the Retention Rate of the First Anti-TNF in Patients with Ankylosing Spondylitis: Two-year Follow-up REGISPONSER-AS
  • Abstract Number: 1156
    Impact of Treatment Experience on Patient Preferences and Disease Burden in Psoriatic Arthritis: Results from a Rheumatology Patient Research Registry
  • Abstract Number: 1682
    Impact of Type, Dose and Duration of Oral Polyunsaturated Fatty Acid Supplementation on Disease Activity in Inflammatory Rheumatic Diseases: A Systematic Literature Review and Meta-analysis
  • Abstract Number: 0260
    Impact on Caregivers of Patients with Juvenile Idiopathic Arthritis: A Hospital-based Study from India
  • Abstract Number: 0033
    Impaired Adipose Tissue Function in Rheumatoid Arthritis: Association with Autoimmunity, Disease Activity and Therapeutic Response
  • Abstract Number: 0180
    Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Computed Tomography in Patients with Systemic Sclerosis
  • Abstract Number: 0179
    Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Tomography Imaging Predicts Adverse Events in Patients with Autoimmune Rheumatic Disease
  • Abstract Number: 1317
    Impairment of Memory in Axial Spondyloarthritis?
  • Abstract Number: 1178
    Implementation of a Dermatologic Manifestations of Connective Tissue Disease Learning Module Including All Skin Tones and Social Determinants of Health for Medical Students: A Pilot Study
  • Abstract Number: 0148
    Implementation of an Interprofessional Safety Check to Screen for Latent Tuberculosis at an Academic Tertiary Referral Rheumatology Clinic Increased Screening Rates Compared to Historical Levels
  • Abstract Number: 0640
    Implementation of Digital Prompt in Electronic Medical Records Improves Pneumonia Vaccination Rates in Patients Prescribed TNF-Inhibitors
  • Abstract Number: 0815
    Implementing Treat to Target (TTT) for Rheumatoid Arthritis (RA) Through a Virtual Learning Collaborative (LC) Program During COVID
  • Abstract Number: 1095
    Improved Arthrocentesis and Fluid Yield of the Non-Effusive Knee Using Pneumatic Compression
  • Abstract Number: 0813
    Improvement in Clinical Disease Activity and Patient-Reported Outcomes After 6 Months of Treatment with Abatacept, Stratified by Line of Therapy, in Patients with RA: Results from a Large, US, National Observational Study
  • Abstract Number: 1375
    Improvement in Overall Survival, Skin Fibrosis and Lung Function with Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis
  • Abstract Number: 1744
    Improvement of Renal and Non-Renal SLE Outcome Measures on Sirolimus Therapy – a 21-year Follow-up Study of 73 Patients
  • Abstract Number: 1257
    Improvements in Abnormal Laboratory Tests Are Associated with Clinical Outcomes in Patients with Active Systemic Lupus Erythematosus
  • Abstract Number: 1788
    Improving Care and Capacity Through Capturing and Recording Patient Reported Outcomes with Digital Solutions in Spondyloarthritis
  • Abstract Number: 1451
    Improving Health Outcomes and Social Connectedness Through Virtual Exercise Programs in Community Members with Musculoskeletal Conditions
  • Abstract Number: 1159
    Improving Healthcare Transition Implementation: Recommendations from Young Patients with Rheumatic Conditions
  • Abstract Number: 0146
    Improving Medication Toxicity Lab Monitoring During the COVID-19 Pandemic
  • Abstract Number: 0648
    Improving Post-Rituximab Hypogammaglobulinemia Risk Assessments: A Fellows’ Quality Improvement Initiative
  • Abstract Number: 0639
    Improving Pre-biologic Infection Screening Using a Best Practice Alert in Electronic Health Records
  • Abstract Number: 1081
    Improving Rheumatology Resource Utilization and Access to Specialty Care for Patients with Early Inflammatory Arthritis Through Enhanced Triage
  • Abstract Number: 0638
    Improving Safety in Rheumatology Patients by Closing Pre-screening Laboratory Care Gaps
  • Abstract Number: 0660
    Improving the Gout Flare Chart Review Using Linked Claims-EHR Data
  • Abstract Number: 1073
    In Favor of the Subspecialty Clinic Model for Rheumatoid Arthritis
  • Abstract Number: 1249
    In Rheumatoid Arthritis, Inhibition of the Lactate Monocarboxylate Transporters-1, and -4 in Pathological Fibroblast-Like Synoviocytes Led to Decreased ChemokineProduction
  • Abstract Number: 0200
    In Undifferentiated Arthritis, DMARD-treatment Intensified During the Last Decennia but Did Not Result in Improved Outcomes
  • Abstract Number: 1928
    In Vitro and In Vivo Evidence for DOCK8 as a Risk Allele for Cytokine Storm Syndrome, Including COVID-19 and MIS-C

  • Abstract Number: 1406
    Incidence and General Clinical Features of Giant Cell Arteritis in the ARTESER Multicenter Study
  • Abstract Number: 1022
    Incidence of Antisynthetase Syndrome and Risk of Malignancy in a Population-based Cohort (1998-2019)
  • Abstract Number: 1684
    Incidence of Infections in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
  • Abstract Number: 1865
    Incidence, Prevalence, and Mortality of Chronic Periaortitis: A Population-based Study
  • Abstract Number: 0689
    Incidence, Prevalence, and Mortality of Dermatomyositis: A Population-based Cohort
  • Abstract Number: 1466
    Increased Adverse Maternal Postpartum Outcomes in Systemic Lupus Erythematosus Pregnancies Compared to Controls
  • Abstract Number: 1659
    Increased All-Cause Mortality Risk in Patients with Incident Rheumatoid Arthritis After First Antidepressant Dispensing: Results from the Nationwide DANBIO Database
  • Abstract Number: 0019
    Increased Circulating CD39+FoxP3+CD4+ Treg Cells in Early Rheumatoid Arthritis Facilitate the Antiinflammatory Action of Methotrexate
  • Abstract Number: 1643
    Increased Incidence of Pediatric SLE and Other Interferon Activated Diseases During COVID-19 Pandemic
  • Abstract Number: 1907
    Increased Otoferlin Expression in B Cells Is Associated with Muscle Weakness in Untreated Juvenile Dermatomyositis: A Pilot Study
  • Abstract Number: 1670
    Increased Prevalence of Gastroesophageal Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
  • Abstract Number: 0293
    Increased Prevalence of Scleroderma Specific Autoantibodies in Seropositive Rheumatoid Arthritis with Lung Involvement
  • Abstract Number: 0565
    Increased Risk for Inflammatory Arthritis in Veterans with Depression or Anxiety
  • Abstract Number: 0128
    Increased Risk of Major Adverse Cardiac Events in Patients with Systemic Lupus Erythematosus After Non-Cardiac Surgery
  • Abstract Number: 0427
    Increased Risk of Severe Infections and Mortality in Patients with Newly Diagnosed Anti-neutrophil Cytoplasmic Antibody–associated Vasculitis: A Population-based Study
  • Abstract Number: 0719
    Increased Risk of Venous Thromboembolism in Adult Patients with Idiopathic Inflammatory Myopathies
  • Abstract Number: 1304
    Increased Risk of Vertebral Fracture Among Patients with Psoriatic Arthritis: A Systematic Review and Meta-analysis
  • Abstract Number: 0998
    Increasing Age Impairs the Metabolic Adaptation of Human Neutrophils to Glucose Deprivation
  • Abstract Number: 1755
    Increasing Participation of Underrepresented Groups in Lupus Clinical Trials: Insights from Qualitative Interviews with Patients and Physicians
  • Abstract Number: 1711
    Increasing Preeclampsia Knowledge in SLE with a Specific Educational Tool: Preliminary Results
  • Abstract Number: 1648
    Increasing Rates of Positivity of Autoantibodies Indicates a Shorter Time-to-Diagnosis of Future Rheumatoid Arthritis
  • Abstract Number: 0627
    Increasing Rates of Standardized Depression Screening in Adolescents and Young Adults with Childhood-Onset Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic
  • Abstract Number: 0424
    Incremental Healthcare Costs of Eosinophilic Granulomatosis with Polyangiitis (EGPA) Compared to Asthma: Retrospective Analysis of Commercial Claims Data in the United States (US)
  • Abstract Number: 0918
    Individual Components Contributing to the Achievement of Assessment in SpondyloArthritis International Society 40 Response in Biologic Naïve Patients with Radiographic Axial Spondyloarthritis: Results from the COAST V Trial
  • Abstract Number: 1586
    Individuals with Pre-arthritic Hip Pain Walk with Hip Motion Alteration Common in Individuals with Hip OA
  • Abstract Number: 0802
    Infection in Rheumatoid Arthritis Patients Treated with Golimumab
  • Abstract Number: 0992
    Inflammatory Arthritis in HIV-Infected Humanized Mice
  • Abstract Number: 1505
    Inflammatory Dendritic Cell and Th17 Polarization in Mouse Model of Lupus Nephritis
  • Abstract Number: 0920
    Influence of Baseline Demographics on Improvements in Disease Activity Measures in Patients with Ankylosing Spondylitis Receiving Upadacitinib: A Post Hoc Subgroup Analysis
  • Abstract Number: 0192
    Influence of Canakinumab Dosing on Efficacy and Safety of Long-term Treatment in Patients with Familial Mediterranean Fever – Interim Analysis of the RELIANCE Registry
  • Abstract Number: 0191
    Influence of Canakinumab Dosing on Long-term Efficacy and Safety in Patients with Cryopyrin-associated Periodic Syndromes (CAPS) – 30-months Interim Analysis of the RELIANCE Registry
  • Abstract Number: 0470
    Inhibition of Toll-Like Receptor 7 (TLR7) with the Potent and Selective Inhibitor of Human TLR7 and TLR8 BMS-986256 Provides Robust Efficacy in Murine Lupus Models, Reversing Established Disease
  • Abstract Number: 1439
    Inhibitors of Endogenous Reverse Transcriptases Suppress in Vitro Type I Interferon Responses and in Vivo Antigen-specific T Cell Responses
  • Abstract Number: 1896
    Initial Results from the Implementation of a National Hydroxychloroquine Safe Prescribing Dashboard Within the Veterans Health Administration
  • Abstract Number: 0995
    Innate Immune Tolerance Attenuates Zymosan-Induced Arthritis, Inflammatory Gene Expression and Synovial Neutrophil Infiltration
  • Abstract Number: 0562
    Inpatient Epidemiology and Resource Utilization of Ankylosing Spondylitis: National Inpatient Sample 2018
  • Abstract Number: 0895
    Insight into Intraindividual Variability Across Neuropsychological Tests and Its Association with Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus
  • Abstract Number: 0546
    Integrated Analysis of Dermal Blister Fluid Proteomics and Genome-wide Skin Gene Expression Gives New Insight into Pathogenesis of Systemic Sclerosis
  • Abstract Number: 1687
    Integrated Laboratory Abnormality Profiles of Upadacitinib with up to 4.5 Years of Exposure in Patients with Rheumatoid Arthritis Treated in a Phase 3 Clinical Trial
  • Abstract Number: 1698
    Integrated Safety Analysis Update for Filgotinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Receiving Treatment over a Median of 2.2 Years
  • Abstract Number: 0966
    Integrated Single Cell RNA-Sequencing Analysis of Tissue-Localized T Cells in Cutaneous Lupus and Lupus Nephritis
  • Abstract Number: 0050
    Integrative Analysis of mRNAs to Identify Sex Differences in Th-17 Mediated Inflammation in Ankylosing Spondylitis
  • Abstract Number: 1128
    Inter-relationships Between Multiple Joint Osteoarthritis and Collagen Biomarkers in Men: The Johnston County Osteoarthritis Project
  • Abstract Number: 1647
    Interaction Effect of Systemic Inflammation and Dietary Protein Intake on Resting Energy Expenditure in Individuals with RA
  • Abstract Number: 1908
    Interferon (IFN)-Stimulated Gene 15: A Novel Biomarker for Lymphoma Development in Sjögren’s Syndrome
  • Abstract Number: 0528
    Interferon Pathway Lupus Risk Alleles Modulate Risk of Death from Acute COVID-19
  • Abstract Number: 1770
    Interim Analysis of Cohort 1 in the Mesenchymal Stromal Cell Trial in Systemic Lupus Erythematosis: Safety and Data Management During the Pandemic
  • Abstract Number: 0127
    Interleukin 1 Receptor Antagonist (IL-1Ra) Variable Number of Tandem Repeat (VNTR) Polymorphism in Fibromyalgia Patients in South India
  • Abstract Number: 1131
    Interleukin 6 Concentration in Synovial Fluid and Its Clinical Significance
  • Abstract Number: 1577
    Interleukin-37: Associations of Plasma Levels and Genetic Variants in Gout
  • Abstract Number: 0030
    Interleukin-9 Enhances the Osteoclastogenesis in Rheumatoid Arthritis
  • Abstract Number: 1318
    Interplay Between Covid-19 and Spondyloarthritis or Its Treatment
  • Abstract Number: 0430
    Interstitial Lung Disease in ANCA-Associated Vasculitis: Associated Factors and Outcomes
  • Abstract Number: 0752
    Intervening on Adverse Childhood Experiences in SLE—Self-Efficacy as a Potential Target
  • Abstract Number: 0623
    Intervention to Improve SLE Medication Adherence
  • Abstract Number: 1468
    Intra-articular (IA) Injection of Empty Large Multilamellar Vesicles Liposomes Reduces Cartilage Degeneration in Rat Osteoarthritis Model
  • Abstract Number: 0728
    Intra-articular Canakinumab (anti-interleukin-1β) for Treatment of Symptomatic Knee Osteoarthritis: A Randomized, Double-blind, Placebo and Naproxen-controlled Phase II Study
  • Abstract Number: 0219
    Intra-Articular Mineralization on Knee CT and Risk of Cartilage Loss: The Multicenter Osteoarthritis Study
  • Abstract Number: 1934
    Intra-Individual Change in Cognitive Function Among Adults with Systemic Lupus Erythematosus: A Markov Analysis over 7 Years
  • Abstract Number: 1191
    Introduction of a Joint Injection and Ultrasound Workshop for Internal Medicine Trainees
  • Abstract Number: 1867
    Investigating Adenosine Deaminase 2 Activity in Large Vessel Vasculitis
  • Abstract Number: 0023
    Investigating Temporal Changes in Pregnancy Among Women with Rheumatoid Arthritis and Healthy Women Using Co-expression Network Analysis
  • Abstract Number: 0556
    Investigating the Heterogeneity of Skin Macrophages in Systemic Scleroderma
  • Abstract Number: 0878
    Investigating the Neutrophil to Lymphocyte Ratio as a Marker of SLE Disease Activity, Health-Related Quality of Life and Depression
  • Abstract Number: 1511
    Investigation of Antigen Specific CD4+ T Cells in Patients with Idiopathic Inflammatory Myopathies
  • Abstract Number: 0686
    Is It Useful to Assess Muscle Involvement with Positron Emission Tomography in Patients with Idiopathic Inflammatory Myositis? A Case-Control Study
  • Abstract Number: 1449
    Is Repeat Serum Urate Testing Superior to a Single Test to Predict Incident Gout over Time?
  • Abstract Number: 0620
    Is There a Difference in Disease Activity Between Genders in Axial Spondyloarthritis? 6-year Longitudinal Data from a Large National Cohort
  • Abstract Number: 0678
    Is There a Difference in Self-reported Flare Frequency Between Men and Women?
  • Abstract Number: 0250
    Is There a Need for a New Classification Criteria in Juvenile Spondyloarthritis?
  • Abstract Number: 1187
    Is Your Program Website Optimized for Recruitment? An Evaluation of Rheumatology Fellowship Program Websites
  • Abstract Number: 1775
    Isolated Axial versus Concomitant Peripheral Disease in Psoriatic Arthritis
  • Abstract Number: 0400
    Item Development for the Assessment of Systemic Sclerosis-associated Raynaud’s Phenomenon (ASRAP) Questionnaire
  • Abstract Number: 0401
    Item Reduction for the Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaire Using Data from the International Multicentre ASRAP Validation Study
  • Abstract Number: 1766
    Itolizumab-induced Modulation of Cell Surface CD6 Is a Pharmacodynamic Marker of Drug Activity in SLE Patients
  • Abstract Number: 1750
    Itolizumab, a Novel anti-CD6 Therapy, in Systemic Lupus Erythematosus Patients: Interim Safety Results from the Phase 1b EQUALISE Dose-escalation Study
  • Abstract Number: 1347
    Ixekizumab Efficacy in Patients with Psoriatic Arthritis Presenting with Symptoms Indicative of Axial Involvement
  • Abstract Number: 0919
    Ixekizumab Shows a Distinct Pattern of Pain Improvement Beyond Measurable Inflammation as Assessed by MRI or CRP or BASDAI Questions 5 & 6 in Patients with Ankylosing Spondylitis
  • Abstract Number: 1341
    Ixekizumab Shows a Pattern of Pain Improvement in Patients with and Without Measurable Inflammation in Psoriatic Arthritis
Jump to:  View All • a b c d e f g h [i] j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology